无人性乙原蛋白协同抑制肝细胞癌与索拉芬尼布
Rong-Sheng Li1, Ling-Yun Li1, Xiao-Feng Zhu1
1School of Pharmacy, Fudan University, Shanghai 201203, China.
Journal of natural products
|January 18, 2024
概括
安诺纳蒙塔纳种子提取物,特别是安诺纳,在晚期肝细胞癌 (HCC) 中与索拉费尼布具有协同作用. 这种组合增强了抗瘤活性,并促进了亡,提供了潜在的新疗法.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 索拉费尼布是晚期肝细胞癌 (HCC) 的标准治疗方法,但在疗效和副作用方面存在局限性.
- 结合疗法正在探索,以提高索拉费尼布的有效性和降低毒性.
研究的目的:
- 调查安诺纳山种子提取物与索拉费尼布对先进HCC的协同抗瘤活性.
- 从Annona montana中分离和识别活性化合物,并评估它们在组合治疗中的潜力.
主要方法:
- 安诺纳山种子提取物的生物指导分化.
- 隔离和结构阐明七个年轻的乙原蛋白,包括三个新化合物.
- 在体外和体内测试以评估与索拉费尼布的协同细胞毒性和抗瘤活性.
- 转录组分析以预测annonacin的作用机制.
主要成果:
- 七种乙原蛋白,包括muricin P,Q和R,被分离和鉴定出来.
- 安诺纳和穆里辛P通过降低ATP水平并诱导亡,在体外表现出与索拉费尼布的协同细胞毒性.
- 安诺纳在体内显示出协同作用的抗瘤活性,促进瘤细胞的亡.
- 转录组分析表明SLC33A1是HCC.中annonacin的一个潜在分子标.
结论:
- 来自Annona montana的Annonacin与索拉费尼布对先进的HCC表现出协同的抗瘤活性.
- 安诺纳可能通过降低ATP水平,促进细胞亡,并可能准SLC33A1.1.
- 安诺纳是高级HCC治疗中组合治疗的有希望的候选人.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
8.4K
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
